Clinical Trial: NCT06663306
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Shanghai Chest Hospital |
| Information Provided By: | Shanghai Chest Hospital |
| Last Update Posted: | 2026-03-02 |
Study Overview
Brief Summary
This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
Official Title
Efficacy and Safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
Conditions
Lung Cancer (NSCLC), Leptomeningeal Metastasis
Intervention / Treatment
- Drug: Pemetrexed
- Drug: Bevacizumab
Other Study ID Numbers
- IS24103
Start Date (Actual)
2024-12-09
Primary Completion Date (Estimated)
2027-12-30
Study Completion Date (Estimated)
2027-12-30
Enrollment (Estimated)
19
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Shanghai Chest Hospital |
| Information Provided By: | Shanghai Chest Hospital |
| Last Update Posted: | 2026-03-02 |
Study Overview
Brief Summary
This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
Official Title
Efficacy and Safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
Conditions
Lung Cancer (NSCLC), Leptomeningeal Metastasis
Intervention / Treatment
- Drug: Pemetrexed
- Drug: Bevacizumab
Other Study ID Numbers
- IS24103
Start Date (Actual)
2024-12-09
Primary Completion Date (Estimated)
2027-12-30
Study Completion Date (Estimated)
2027-12-30
Enrollment (Estimated)
19
Study Type
Interventional
Phase
Phase 1